Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; …
Over the last 12 months, insiders at Alnylam Pharmaceuticals, Inc. have bought $0 and sold $66.24M worth of Alnylam Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Alnylam Pharmaceuticals, Inc. have bought $0 and sold $43.93M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 595,002 shares for transaction amount of $42.76M was made by Sanofi (10 percent owner) on 2017‑05‑31.
2025-02-18 | Sale | CSO & EVP, Head of Research | 1,440 0.0011% | $251.56 | $362,243 | -0.67% | ||
2025-02-18 | Sale | CMO & EVP Dev & Med Affairs | 1,548 0.0012% | $251.67 | $389,579 | -0.67% | ||
2025-02-14 | Sale | Chief Executive Officer | 1,213 0.0009% | $255.17 | $309,527 | -1.86% | ||
2025-02-14 | Sale | EVP, Chief Financial Officer | 967 0.0007% | $255.17 | $246,750 | -1.86% | ||
2025-02-14 | Sale | CSO & EVP, Head of Research | 663 0.0005% | $255.21 | $169,204 | -1.86% | ||
2025-02-14 | Sale | CMO & EVP Dev & Med Affairs | 1,561 0.0012% | $255.17 | $398,325 | -1.86% | ||
2025-01-27 | Sale | CMO & EVP Dev & Med Affairs | 52,592 0.0421% | $285.00 | $14.99M | -2.07% | ||
2025-01-23 | Sale | director | 11,250 0.0087% | $275.00 | $3.09M | -1.59% | ||
2024-12-12 | Sale | CMO & EVP Dev & Med Affairs | 1,752 0.0014% | $251.00 | $439,760 | +2.39% | ||
2024-11-27 | Sale | CSO & EVP, Head of Research | 1,531 0.0012% | $252.29 | $386,261 | -0.48% | ||
2024-11-26 | Sale | Chief Executive Officer | 5,219 0.004% | $250.98 | $1.31M | -0.17% | ||
2024-11-26 | Sale | EVP, Chief Financial Officer | 1,682 0.0013% | $250.98 | $422,144 | -0.17% | ||
2024-11-26 | Sale | CMO & EVP Dev & Med Affairs | 1,682 0.0013% | $250.98 | $422,144 | -0.17% | ||
2024-11-26 | Sale | CSO & EVP, Head of Research | 1,469 0.0011% | $250.98 | $368,686 | -0.17% | ||
2024-11-26 | Sale | EVP, Chief Commercial Officer | 1,469 0.0011% | $250.98 | $368,686 | -0.17% | ||
2024-08-20 | Sale | Chief Executive Officer | 15,000 0.0117% | $280.00 | $4.2M | -5.29% | ||
2024-08-12 | Sale | CSO & EVP, Head of Research | 22,025 0.0172% | $270.99 | $5.97M | -1.34% | ||
2024-08-06 | Sale | director | 20,250 0.0157% | $262.00 | $5.31M | +1.57% | ||
2024-08-01 | Sale | Chief Executive Officer | 15,148 0.012% | $270.00 | $4.09M | -0.75% | ||
2024-07-11 | Sale | Chief Executive Officer | 7,093 0.006% | $261.00 | $1.85M | +1.43% |
PYOTT DAVID E I | director | 136 0.0001% | $250.59 | 1 | 1 | +45.98% |
SHARP PHILLIP A | director | 0 0% | $250.59 | 2 | 15 | +68.46% |
Sanofi | 10 percent owner | 10554134 8.1526% | $250.59 | 6 | 0 | +18.68% |
NOVARTIS AG | 10 percent owner | 4051002 3.1292% | $250.59 | 3 | 1 | <0.0001% |
Westphal Christoph H | director, 10 percent owner | 300170 0.2319% | $250.59 | 1 | 0 | +16.38% |
Increased Positions | 334 | +59.12% | 13M | +10.51% |
Decreased Positions | 243 | -43.01% | 9M | -7.36% |
New Positions | 97 | New | 6M | New |
Sold Out Positions | 66 | Sold Out | 739,081 | Sold Out |
Total Postitions | 656 | +16.11% | 128M | +3.15% |
Capital World Investors | $4.26M | 12.87% | 16.6M | +92,101 | +0.56% | 2024-12-31 |
Fmr Llc | $3.46M | 10.45% | 13.49M | -1M | -8.09% | 2024-12-31 |
Vanguard Group Inc | $3.27M | 9.87% | 12.73M | +98,303 | +0.78% | 2024-12-31 |
Blackrock, Inc. | $2.54M | 7.66% | 9.89M | +177,839 | +1.83% | 2024-12-31 |
Capital Research Global Investors | $1.79M | 5.4% | 6.97M | +2M | +32.89% | 2024-12-31 |
Regeneron Pharmaceuticals, Inc. | $1.14M | 3.45% | 4.44M | +4M | New | 2024-12-31 |
T. Rowe Price Investment Management, Inc. | $1.12M | 3.4% | 4.38M | +1M | +39.66% | 2024-12-31 |
Wellington Management Group Llp | $1.08M | 3.25% | 4.2M | -756,724 | -15.28% | 2024-12-31 |
Baillie Gifford & Co | $1.04M | 3.13% | 4.04M | -846,741 | -17.33% | 2024-12-31 |
Dodge & Cox | $907,900.00 | 2.74% | 3.54M | -82,273 | -2.27% | 2024-12-31 |